Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Rat|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant protein encoding the N-terminal region of human CD29|
|Storage buffer||tissue culture supernatant|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:15-1:30|
|Western Blot (WB)||1:500|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 1 publications below|
MA5-11429 targets CD29 in IHC (P) and Western blot applications and shows reactivity with Human and Rat samples.
The MA5-11429 immunogen is recombinant protein encoding the N-terminal region of human CD29.
MA5-11429 has been used successfully in the western blot analysis of integrin beta 1 (CD29) using human cells lysates.
CD29 or the integrin Beta-1 belongs to the family of cell adhesion receptors. It was initially characterized independently as protein gpIIa appearing on platelets, as the common Beta subunit of the very late activation antigen (VLA), and as a component of various protein complexes binding to extracellular matrix proteins. The CD29 is expressed at the cell surface exclusively as part of a heterodimer, in association with one of at least nine different integrin alpha subunits (alpha, alpha, alpha, alpha, alpha, alpha, alpha, alpha, and alphav). With the exception of red blood cells and possible weak expression on granulocytes, CD29 is expressed nearly all cell and tissue types.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer.
MA5-11429 was used in immunohistochemistry to investigate the mechanism of cancer risistance to trastuzumab
|Lesniak D,Xu Y,Deschenes J,Lai R,Thoms J,Murray D,Gosh S,Mackey JR,Sabri S,Abdulkarim B||Cancer research (69:8620)||2009|
beta OL; beta oligodendroglia; CD29; fibronectin receptor subunit beta; FNRB; glycoprotein IIa; GPIIA; integrin beta 1; integrin beta 1 (fibronectin receptor beta); integrin beta-1; integrin VLA-4 beta subunit; integrin VLA-4 subunit beta; integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12); ITGB1; MDF2; MSK12; very late activation protein, beta polypeptide; VLA-4 subunit beta; VLA-BETA; VLAB
CD29; FNRB; GPIIA; ITGB1; MDF2; MSK12; VLA-BETA; VLAB